

Base Demand Forecast

“v17”, prepared in 2019



December, 2019

Reach every child

www.gavi.org

Introduction

This is the fourth publication of the Base Demand Forecast that describes the volume projections that inform Gavi's financial forecast and impact projections. Whilst prepared at the individual vaccine level, this forecast takes an aggregate view across the Gavi portfolio. This publication was prepared in 2019 and aligns with the "v17" financial forecast cycle. It covers the majority of Gavi programs.¹

The publication is intended to improve the transparency and timeliness of demand forecasts shared with Gavi partners, industry and the public. The Base Demand Forecast is published annually following Gavi's 4th quarter Board meeting where the financial forecast is reviewed. In general, the forecast will be published in December or January each year.

This publication includes tables describing volumes associated with two different country scopes. The first table summarizes volumes for forecasts that generally considered the 73 countries that were eligible for Gavi support as of 2011. This set of countries is labelled "Gavi 73". The second table summarizes actual and forecasted volumes that considered 64 countries, defined as the same "Gavi 73" countries but excluding India, Indonesia, Ukraine and six Pan American Health Organization (PAHO) countries. The "Gavi 64" country scope is designed to help improve the consistency across actuals and forecasted periods given that shipments reported by UNICEF are often limited in scope to the 64 countries.

The volumes presented include doses regardless of actual or projected funding source. The figures include doses projected to be funded by Gavi and doses co-financed by supported countries. In addition, the volumes include doses projected to be fully self-financed by countries that have transitioned from Gavi support, as well as estimated demand for programmes that introduce without Gavi support. Volumes reflect supply constraints where relevant.

There are a number of important nuances in the volume forecasts that have been footnoted to the extent possible. In general, the base demand forecast publication seeks to find a balance on describing some of the key complexities while still keeping this publication relatively simple for its intended purpose. Nevertheless, we recognize there may be additional details and explanation that will be required for some audiences and purposes. Users of this new publication can contact forecast@gavi.org if they require further guidance or information.

Feedback and suggestions for improvement on this new demand forecast publication are also welcomed. Please send comments to forecast@gavi.org.

¹ Excludes YF and Men A stockpiles, Vaccine Investment Strategy (VIS), Ebola and Malaria vaccines.

Total Gavi 73 Volume by Vaccine, doses, millions

Table A. Total Volumes for "Gavi 73" by Vaccine, doses, millions

Vaccine	Forecasted										Total
	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	
Pneumococcal conjugate vaccine (PCV)	146	156	159	175	210	206	217	219	216	217	1,921
Hexavalent Vaccine (Hexa)	0	0	0	0	0	3	19	42	68	92	225
Pentavalent (DTP-Hib-HepB)	230	240	229	233	238	239	233	217	198	180	2,237
Inactivated Polio Vaccine (IPV)	73	76	81	85	98	113	104	93	81	70	874
Rotavirus	151	153	172	178	187	193	202	207	206	207	1,856
Measles-Rubella (MR)	330	129	179	185	170	236	188	208	277	229	2,131
Measles	92	65	72	86	57	52	65	63	33	28	613
Human papillomavirus (HPV)	13	13	13	16	33	48	68	91	76	71	439
Meningitis A (MenA)	45	12	27	63	33	35	36	37	38	39	365
Yellow Fever (YF)	56	70	61	69	68	70	73	67	67	65	664
Japanese encephalitis (JE)	34	34	40	39	46	48	42	56	54	53	445
Typhoid Conjugate Virus (TCV)	13	37	52	37	34	44	72	32	39	36	398
Total of above	1,183	986	1,085	1,165	1,175	1,285	1,318	1,332	1,355	1,286	12,169

Sources

Forecasted doses are from the demand forecast used to inform the v17 Gavi financial forecast reviewed by the Gavi Board at its December 2019 meeting

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The figures above reflects assumptions aligned with the Financial Forecast v17. However it is one of multiple scenarios of plausible demand. (HPV, TCV, YF, DTwP containing and Inactivated Polio containing vaccines represent one scenario considered in their respective SDSs. Kindly refer to the latest SDSs for further information.)
- The country scope considered for MenA, YF and JE are limited to the geographies where these regional programs focus.
- Stockpile volumes are not reflected in above volumes in Men A and YF.
- Hexavalent demand by Gavi supported countries is subject to a funding window opened by the Gavi board. Assumes 3 + 1 doses. The impact of Hexavalent demand is reflected on Pentavalent and IPV vaccine volumes respectively.
- IPV assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations and transition to 2 full IPV doses from 2021.

Total Gavi 64 Volume by Vaccine, doses, millions

Table B. Total Volumes for "Gavi 64" by Vaccine, doses, millions

Vaccine	Actuals								Forecasted								Total		
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026		2027	2028
Pneumococcal conjugate vaccine (PCV)	26	44	62	103	119	128	147	131	127	116	111	117	126	121	133	135	133	134	2,014
Hexavalent Vaccine (Hexa)	0	0	0	0	0	0	0	0	0	0	0	0	0	3	19	39	57	79	198
Pentavalent (DTP-Hib-HepB)	119	144	160	134	151	151	149	133	134	144	134	138	143	146	140	126	113	97	2,455
Inactivated Polio Vaccine (IPV)				4	31	30	38	57	67	61	65	69	77	93	84	75	66	57	875
Rotavirus		8	18	37	37	38	50	59	59	64	83	89	97	100	105	105	107	107	1,162
Measles-Rubella (MR)			88	86	38	12	60	34	102	51	99	104	90	156	107	128	197	147	1,498
Measles		10	115	22	44	37	22	79	92	65	72	86	57	52	65	63	33	28	942
Human papillomavirus (HPV)			1	1	1	2	2	6	12	12	12	16	27	37	47	65	53	48	342
Meningitis A (MenA)		56	53	68	31	36	18	21	45	12	27	63	33	35	36	37	38	39	648
Yellow Fever (YF)	14	15	21	27	24	26	20	48	56	70	61	69	68	70	73	67	67	65	859
Japanese encephalitis (JE)					2	9	16	1	4	3	7	5	12	12	5	18	15	13	120
Typhoid Conjugate Virus (TCV)									13	37	52	37	34	44	72	32	39	36	398
Total of above	159	279	517	481	478	468	521	568	712	637	724	792	765	866	885	890	917	849	11,510

Sources

Actual volumes are based on shipment reports published by UNICEF Supply Division (as of June 2019). Forecasted volumes are from the demand forecast aligned with the v17 Gavi Financial Forecast reviewed by the Gavi Board at its December 2019 meeting.

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The scope of countries considered in actuals and forecasted values is generally 64 countries: the "Gavi 73" less India, Indonesia, Ukraine, and six PAHO countries.
- Actual volumes should be interpreted as minimums in some vaccines where programs are fully-self funded by countries or procured through channels other than UNICEF SD.
- The figures above reflects assumptions aligned with the Financial Forecast v17. However it is one of multiple scenarios of plausible demand (HPV, TCV, YF, DTwP containing and Inactivated Polio containing vaccines represent one scenario considered in their respective SDSs. Kindly refer to the latest SDSs for further information.)
- The country scope considered for MenA, YF and JE are limited to the geographies where these regional programs focus.
- Stockpile volumes are not reflected in above volumes in Men A and YF.
- Hexavalent demand by Gavi supported countries is subject to a funding window opened by the Gavi board. Assumes 3 + 1 doses. The impact of Hexavalent demand is reflected on Pentavalent and IPV vaccine volumes respectively.
- IPV assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations and transition to 2 full IPV doses from 2021.

Thank you



Reach every child

www.gavi.org